Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Next Previous
X
Search
Trial Profile

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PRIMO
  • Sponsors Secura Bio; Verastem Oncology

    • Most Recent Events

    • 09 Dec 2024 According to Secura Bio media release, data from this trial presented at the 2024 American Society of Hematology (ASH) Annual Meeting
    • 09 Dec 2024 Results of 123 patients in the dose expansion phase of the PRIMO Phase 2 clinical trial presented in the Secura Bio Media Release
    • 06 Nov 2024 According to Secura Bio media release, the company will present a poster of final results from the PRIMO trial highlighting the outcomes of 123 patients in the dose expansion phase at the upcoming 2024 American Society of Hematology (ASH) Annual Meeting taking place on December 7-10, 2024 in San Diego, CA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top